重症患者生物标志物应用全景:急性肾损伤的系统证据图及实践启示
成人占78.6%,93.3%为队列设计;混合重症、心脏手术和脓毒症是最常研究的临床场景(69.5%)。证据图按用途合成:预测AKI(n=944)、预后(n=647)、病因诊断(n=109)、富集临床试验(n=6)、管理AKI(n=12)。结论认为生物标志物诊断准确性证据充足,但临床实践试验少;可用于监测高危患者(如手术及多重肾毒性药物暴露者),并指出未来需管理性和富集试验。
要点
- 该系统证据图纳入1116项研究,93.3%为队列设计,成人占78.6%,证据以预测AKI为主(n=944)。
- 管理AKI的生物标志物研究仅12项,富集临床试验仅6项,实践性证据明显不足。
- 最常研究的临床场景为混合重症、心脏手术和脓毒症,合计占69.5%的研究。
- 原文指出可从生物标志物用于重症患者管理的评估中获取实施策略,尤其在外科和肾毒性药物暴露人群。
- 原文强调需未来管理性和富集试验来弥合预测准确性与临床决策之间的差距。
适用人群与场景
- 成人重症患者(占研究78.6%),研究场景包括混合重症、心脏手术和脓毒症(合计69.5%的研究)。
- 原文提及实施策略针对AKI风险监测人群,包括接受手术的患者和暴露于多种肾毒性药物的患者。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文提及实施策略包括对AKI风险患者进行监测,包括接受手术的患者和暴露于多种肾毒性药物的患者;未给出具体药物、剂量或流程。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 纳入研究涉及一种或多种新型肾损伤生物标志物与AKI;成人占78.6%,93.3%为队列设计。
- 证据图按用途合成:预测AKI(n=944)、预后临床结局(n=647)、诊断AKI病因(n=109)、富集临床试验(n=6)、管理AKI(n=12)。
- 最常研究的临床场景为混合重症、心脏手术和脓毒症,占69.5%的研究。
- 结论指出生物标志物诊断准确性证据充足,但临床实践试验较少;实施策略可从用于重症患者管理的评估中获取,尤其在外科和肾毒性药物暴露人群。
证据类型、等级与局限
- 证据类型为系统证据图(mapping review),基于临床试验和观察性研究,未报告证据等级或推荐强度。
- 局限:原文指出实践性试验少(管理AKI n=12,富集试验n=6),预测准确性与临床决策之间存在差距,需未来管理性和富集试验。
对床旁实践的改变
- 原文提示可在外科手术患者和暴露于多种肾毒性药物的重症患者中,考虑使用新型肾损伤生物标志物进行AKI风险监测;但具体实施方法需参考相关评估研究,原文未给出具体阈值或方案。
- 原文指出当前证据多集中于预测AKI准确性,实践性试验少,临床决策中应用生物标志物需谨慎,仍需未来管理性试验验证。
指南或共识出处
- 原文未提及具体指南或共识名称;来源为Crit Care Med发表的系统证据图。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Create systematic evidence maps of novel biomarkers of kidney injury from a mapping review to guide future implementation in patient care.
DATA SOURCES: PubMed/MEDLINE and Embase.
STUDY SELECTION: Systematic evidence maps included clinical trials and observational studies in critically ill patients, investigating novel kidney biomarkers for acute kidney injury (AKI).
DATA EXTRACTION: Six thousand eight hundred five records were screened, and 1116 studies were included that related to one or more novel biomarkers and AKI.
DATA SYNTHESIS: Adult populations accounted for 78.6% of the studies, and 93.3% used a cohort design to investigate AKI biomarkers. Mixed critically ill populations, cardiac surgery, and sepsis were identified as the most frequently studied clinical contexts in 69.5% of the studies. Systematic evidence maps were synthesized for biomarker studies to predict AKI (n = 944), prognosticate clinical outcomes (n = 647), diagnose AKI etiology (n = 109), enrich clinical trials (n = 6), and manage AKI (n = 12). Implementation strategies for patient care included surveilling patients at risk of AKI, including patients undergoing surgery and those exposed to multiple nephrotoxic drugs.
CONCLUSIONS: Substantial clinical evidence assessing the accuracy of biomarkers compared with diagnosis of AKI exists, with fewer practical trials in clinical use. Still, guidance on implementation approaches can be gleaned from evaluations using biomarkers for the management of critically ill patients, particularly in surgical and nephrotoxin-exposed populations where evidence is available. This review identifies the landscape of current evidence and highlights priorities for future management and enrichment trials needed to bridge the gap between predictive accuracy and clinical decision-making.
参考来源
- Kane-Gill SL, Boyer KM, Akcan Arikan A, et al. Landscape of Biomarker Use in Critically Ill Patients: Systematic Evidence Map of Acute Kidney Injury and Implications for Practice. Crit Care Med. 2026. PMID: 42725835. doi:10.1097/CCM.0000000000007362
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。